FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a chimeric peptide which is capable of reducing glucose levels in a subject, as well as a pharmaceutical composition containing such a peptide and a pharmaceutically acceptable carrier. Chimeric polypeptide according to the invention can also be used for treating a hyperglycaemic condition, for improving glucose metabolism, for treating non-alcoholic steatohepatitis, for treating insulin resistance, for treating hyperinsulinemia.
EFFECT: invention allows extending the range of products for treating hyperglycemic conditions.
300 cl, 8 dwg, 9 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES | 2013 |
|
RU2675514C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING PEPTIDE VERSIONS, AND METHODS OF USING THEM | 2015 |
|
RU2729161C2 |
| CANCER MODELS AND CORRESPONDING METHODS | 2014 |
|
RU2707531C2 |
| CHIMERIC FIBROBLAST GROWTH FACTORS WITH CHANGED RECEPTOR SPECIFICITY | 2010 |
|
RU2573896C2 |
| BINDING PROTEINS AND METHODS FOR USE THEREOF | 2015 |
|
RU2701434C2 |
| FGF21 MIMETIC ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2774368C2 |
| METHODS OF TREATING METABOLIC DISORDERS USING FGF21 VARIANTS | 2018 |
|
RU2815403C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING METABOLIC SYNDROME | 2011 |
|
RU2593960C2 |
| ANTI-CXCR3 ANTIBODIES | 2013 |
|
RU2663141C2 |
| ANTIBODY SPECIFICALLY BINDING TO GLP-1R AND FUSION PROTEIN THEREOF WITH GLP-1 | 2014 |
|
RU2681857C2 |
